The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 45 | Should AI prognostic models guide adjuvant chemotherapy in colorectal cancer?
Murtaza Makasarwala, MBBS, FACS, Shalby Multispecialty Hospital, Surat, India, discusses the limitations of relying solely on artificial intelligence (AI) prognostic models in colorectal cancer, highlighting that these models are based on observational cohorts rather than trial-based evidence. His systematic review, which compared AI prognostic models with clinical pathological factors, yielded a concordance index that outperformed the TNM staging concordance index, but AI models should not be used to avoid adjuvant chemotherapy without regional validation and randomized control trial evidence. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
